RxDoctor Payments Data

Lindsay Ferguson, MD

Gynecologic Oncology · Cleveland, OHNPI 1134548100

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Johnson & Johnson at 40.4% of the total. Reporting peaked in 2024 at $283 and has fallen 75.3% since, to $70 in 2025. That places this record below the midpoint for gynecologic oncology clinicians in OH, where the typical reported total is $1,215.

$467in general payments, 2019–2025

Across 10 payments — averaging $46.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$189
  • AbbVie$102
  • Conmed Corporation$84
  • Intuitive Surgical$29
  • Eisai Inc.$24
  • Genentech USA, Inc.$23
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$467100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$467 in reported general payments places this provider in the 30th percentile of 62 gynecologic oncology providers in Ohio.

See all gynecologic oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$95,637
Medicare patients
185
Services billed
591

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LenvimaLenvatinib Mesylate19$465,739
ZejulaNiraparib Tosylate11$204,889
LynparzaOlaparib16$198,433
EliquisApixaban25$17,395
Dexamethasone52$1,288
Estradiol12$960
Ondansetron Hcl23$918
Megestrol Acetate16$623
Prochlorperazine Maleate48$527
Duloxetine Hcl21$246
Oxycodone Hcl40$234
Letrozole16$179
Tramadol Hcl29$77
Fluconazole11$72
Olanzapine24$39

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Eisai Inc.Lenvima$24$465,73919 claims
GSKZejula$16$204,88911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 62 gynecologic oncology providers in Ohio.

Other gynecologic oncology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →